Nightstar Therapeutics (NITE) Earns Daily News Sentiment Rating of 0.17

Media coverage about Nightstar Therapeutics (NASDAQ:NITE) has trended somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nightstar Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.4321734856021 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

NITE has been the topic of a number of recent analyst reports. BMO Capital Markets initiated coverage on Nightstar Therapeutics in a research report on Monday, October 23rd. They issued an “outperform” rating and a $30.00 target price on the stock. Jefferies Group initiated coverage on Nightstar Therapeutics in a research report on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price on the stock. Chardan Capital initiated coverage on Nightstar Therapeutics in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $40.00 target price on the stock. Leerink Swann initiated coverage on Nightstar Therapeutics in a research report on Monday, October 23rd. They issued an “outperform” rating and a $25.00 target price on the stock. Finally, Wedbush initiated coverage on Nightstar Therapeutics in a research report on Monday, October 23rd. They issued an “outperform” rating and a $19.00 target price on the stock. Five research analysts have rated the stock with a buy rating, Nightstar Therapeutics presently has a consensus rating of “Buy” and an average price target of $27.80.

Shares of Nightstar Therapeutics (NASDAQ NITE) traded up $0.01 on Friday, hitting $14.21. The company’s stock had a trading volume of 22,800 shares, compared to its average volume of 34,250. Nightstar Therapeutics has a one year low of $11.99 and a one year high of $24.93. The firm has a market cap of $399.03 and a price-to-earnings ratio of -28.42.

COPYRIGHT VIOLATION NOTICE: “Nightstar Therapeutics (NITE) Earns Daily News Sentiment Rating of 0.17” was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.thestockobserver.com/2018/01/12/nightstar-therapeutics-nite-earns-daily-news-sentiment-rating-of-0-17.html.

About Nightstar Therapeutics

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Insider Buying and Selling by Quarter for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply